Apellis Pharmaceuticals, Inc.
APLS
$41.06
$0.040.10%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 120.23% | -62.16% | 475.52% | -11.93% | -38.84% |
| Total Depreciation and Amortization | -34.75% | -26.85% | -25.82% | -0.67% | 0.45% |
| Total Amortization of Deferred Charges | 11.84% | 11.58% | -3.34% | 157.98% | 677.63% |
| Total Other Non-Cash Items | -8.04% | -19.26% | 2.59% | -21.87% | -24.83% |
| Change in Net Operating Assets | -1,116.41% | -20.51% | -316.69% | 396.84% | 110.05% |
| Cash from Operations | -14.15% | -173.22% | 218.13% | 153.30% | 59.84% |
| Capital Expenditure | -- | -440.00% | -- | 45.56% | 97.27% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -440.00% | -- | 45.56% | 97.27% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -69.40% | -23.23% | -68.82% | 27.22% | -97.03% |
| Repurchase of Common Stock | -214.29% | 100.00% | 71.43% | -- | 75.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -76.64% | 131.48% | -68.80% | -84.56% | -99.75% |
| Foreign Exchange rate Adjustments | -136.49% | 119.07% | -87.28% | 100.29% | 271.77% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -15.63% | -189.33% | 196.47% | -66.17% | -108.86% |